

IN THE CLAIMS:

1-21. (Cancelled)

22. (New) A process for the manufacture of a sulfur-containing medicament composition for administration to a human subject suffering from a disorder or glutathione conjugation, which comprises preparing a physiologically acceptable medicament composition containing as an active ingredient elemental sulfur or acid salts of sulfur, formulated in combination with a pharmaceutically acceptable binder and adapted to release a therapeutically effective quantity of elemental sulfur upon oral ingestion or parenteral administration *in vivo* in a human subject in need thereof for the treatment of a disorder of glutathione conjugation.